Your browser is no longer supported. Please, upgrade your browser.
DCPH Deciphera Pharmaceuticals, Inc. monthly Stock Chart
DCPH [NASD]
Deciphera Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.95 Insider Own0.30% Shs Outstand54.92M Perf Week-5.72%
Market Cap3.03B Forward P/E- EPS next Y-4.93 Insider Trans-80.49% Shs Float37.35M Perf Month-17.39%
Income-157.30M PEG- EPS next Q-1.17 Inst Own67.90% Short Float6.86% Perf Quarter14.79%
Sales25.00M P/S121.04 EPS this Y-72.10% Inst Trans1.00% Short Ratio4.49 Perf Half Y52.72%
Book/sh13.82 P/B3.99 EPS next Y-17.80% ROA-42.10% Target Price66.77 Perf Year108.24%
Cash/sh11.55 P/C4.77 EPS next 5Y21.00% ROE-46.70% 52W Range19.88 - 71.11 Perf YTD-11.47%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-22.51% Beta-
Dividend %- Quick Ratio15.20 Sales past 5Y- Gross Margin- 52W Low177.16% ATR3.00
Employees112 Current Ratio15.20 Sales Q/Q- Oper. Margin- RSI (14)30.64 Volatility3.76% 4.04%
OptionableYes Debt/Eq0.00 EPS Q/Q-97.70% Profit Margin- Rel Volume0.88 Prev Close55.81
ShortableYes LT Debt/Eq0.00 EarningsMar 12 AMC Payout- Avg Volume569.88K Price55.10
Recom1.80 SMA20-13.64% SMA50-13.16% SMA20038.19% Volume503,649 Change-1.27%
Dec-20-19Reiterated Jefferies Buy $53 → $77
Oct-29-19Upgrade SVB Leerink Underperform → Mkt Perform $29 → $34
Oct-22-19Initiated JMP Securities Mkt Outperform
Oct-03-19Initiated H.C. Wainwright Buy $60
Sep-30-19Initiated Jefferies Buy $47
Jul-18-19Initiated Deutsche Bank Buy $42
Dec-31-18Upgrade B. Riley FBR Neutral → Buy $27 → $34
Sep-25-18Initiated Leerink Partners Underperform
Aug-29-18Initiated Raymond James Outperform $47
Jul-05-18Initiated SunTrust Buy
Jun-19-18Downgrade B. Riley FBR, Inc. Buy → Neutral $43
Feb-16-18Initiated B. Riley FBR, Inc. Buy $43
Oct-23-17Initiated Piper Jaffray Overweight $35
Oct-23-17Initiated Nomura Buy
Oct-23-17Initiated JP Morgan Overweight $30
Oct-23-17Initiated JMP Securities Mkt Outperform $38
Feb-20-20 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference Business Wire
Feb-19-20 04:01PM  Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock Business Wire
Feb-13-20 10:12PM  Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock Business Wire -15.78%
01:36PM  Revamped postal center in Waltham will sell for $320M American City Business Journals
10:31AM  Deciphera's NDA for GIST Drug Gets Priority Review From FDA Zacks
08:05AM  The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO Benzinga
Feb-12-20 04:14PM  Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
04:01PM  Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors Business Wire
Jan-13-20 09:00AM  Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2020 Milestones Business Wire
Jan-11-20 06:09PM  How Did Deciphera Pharmaceuticals, Inc. (DCPH) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Jan-06-20 07:00AM  Deciphera Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-02-20 06:40AM  Does Market Volatility Impact Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Share Price? Simply Wall St. -7.05%
Dec-17-19 07:56AM  The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO Benzinga +9.39%
Dec-16-19 07:00AM  Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors Business Wire
Dec-05-19 03:47PM  Hedge Funds Have Never Been This Bullish On Deciphera Pharmaceuticals, Inc. (DCPH) Insider Monkey
Dec-04-19 04:05PM  Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors Business Wire
Nov-26-19 07:00AM  Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman TEST Business Wire Releases
07:00AM  Deciphera Pharmaceuticals Expands its Board of Directors with Appointment of Frank S. Friedman Business Wire
Nov-22-19 08:00PM  Callon, Fitbit, Genco Shipping and Other 13D Filings Barrons.com
Nov-13-19 04:30PM  Deciphera Pharmaceuticals, Inc. to Present Data from DCC-3014 and Ripretinib Programs at the Connective Tissue Oncology Society (CTOS) 2019 Annual Meeting Business Wire
07:00AM  Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences Business Wire
Nov-04-19 05:15PM  Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:01PM  Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results Business Wire
Nov-01-19 10:24AM  3 Strong Buy Stocks Jefferies Thinks Are Set to Rip Higher TipRanks
Oct-30-19 10:15AM  What's in Store for GW Pharmaceuticals (GWPH) in Q3 Earnings? Zacks +8.19%
Oct-29-19 12:30PM  Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Business Wire
07:32AM  The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study Benzinga
Oct-28-19 06:06PM  Did Hedge Funds Drop The Ball On Deciphera Pharmaceuticals, Inc. (DCPH) ? Insider Monkey +8.35%
12:30PM  Deciphera Pharmaceuticals Presents Data from Rebastinib and DCC-3116 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Business Wire
07:00AM  Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 4, 2019 Business Wire
Oct-17-19 10:21AM  Can Sequencing Products Drive Illumina's (ILMN) Q3 Earnings? Zacks
Oct-16-19 04:34PM  Deciphera Pharmaceuticals to Present Data Updates From Portfolio of Kinase Switch Control Inhibitors in Four Poster Sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Business Wire
Oct-15-19 05:07PM  Robotics company Boston Dynamics selects new Waltham HQ American City Business Journals
Oct-04-19 09:00AM  Deciphera Pharmaceuticals, Inc. (DCPH) Moves to Buy: Rationale Behind the Upgrade Zacks
05:56AM  Should Deciphera Pharmaceuticals (NASDAQ:DCPH) Be Disappointed With Their 14% Profit? Simply Wall St.
Oct-02-19 07:00AM  Deciphera Pharmaceuticals Appoints Matthew L. Sherman, M.D. as Executive Vice President and Chief Medical Officer Business Wire
Sep-30-19 09:06AM  Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors Business Wire
Sep-25-19 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the 2019 Cantor Global Healthcare Conference Business Wire
Sep-03-19 04:01PM  Deciphera Pharmaceuticals Announces Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Common Stock Business Wire
Aug-20-19 07:15AM  Deciphera Pharmaceuticals: Buy at the High? Motley Fool
Aug-19-19 04:01PM  Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock Business Wire
Aug-15-19 07:45AM  The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings Benzinga
Aug-14-19 10:43PM  Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock Business Wire +5.49%
04:28PM  This Biotech Is On A Two-Day Sprint; Why An Analyst Prefers Its Rival Investor's Business Daily
09:37AM  Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80% Zacks
Aug-13-19 06:02PM  Deciphera (DCPH) Stock at $62 a Share? Deutsche Bank Thinks Its Possible TipRanks +79.95%
04:31PM  Why Best Buy, Deciphera Pharmaceuticals, and Genworth Financial Jumped Today Motley Fool
04:10PM  This Biotech Stock Rocketed 80% In Bullish Volume On A Cancer Drug Investor's Business Daily
04:01PM  Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
01:57PM  Here's Why Deciphera Pharmaceuticals Rose as Much as 115% Today Motley Fool
12:55PM  Deciphera Soars on Positive Phase III Drug Trial TheStreet.com
12:46PM  Deciphera shares skyrocket as cancer drug improves progression-free survival Reuters
12:28PM  A Look At Benzinga Pro's Most-Searched Tickers For August 13, 2019 Benzinga
10:19AM  Deciphera stock surges on gastrointestinal cancer drug success American City Business Journals
08:44AM  Deciphera Pharmaceuticals stock more than doubles on heavy volume after positive trial data MarketWatch
07:33AM  UPDATE 3-Deciphera shares skyrocket as cancer drug improves progression-free survival Reuters
07:10AM  Deciphera Pharma's late-stage stomach cancer study meets main goal Reuters
07:05AM  Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors Business Wire
07:00AM  Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors Business Wire
Aug-02-19 07:00AM  Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results Business Wire
Jul-26-19 08:42AM  Implied Volatility Surging for Deciphera (DCPH) Stock Options Zacks
Jul-08-19 04:05PM  Deciphera Pharmaceuticals, Inc. Announces Appointment of Susan L. Kelley, M.D., to its Board of Directors Business Wire
Jul-05-19 04:39PM  Is Deciphera Pharmaceuticals, Inc. (DCPH) A Good Stock To Buy? Insider Monkey
10:06AM  Options Traders Expect Huge Moves in Deciphera Pharmaceuticals (DCPH) Stock Zacks
Jun-18-19 08:41AM  Options Traders Expect Huge Moves in Deciphera Pharmaceuticals (DCPH) Stock Zacks
Jun-11-19 07:00AM  Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China GlobeNewswire
07:00AM  Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China Business Wire
Jun-10-19 07:00AM  Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers Business Wire
May-30-19 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Global Healthcare Conference Business Wire
May-14-19 04:05PM  Deciphera Pharmaceuticals, Inc. to Present at the UBS Global Healthcare Conference Business Wire
May-09-19 04:05PM  Deciphera Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results Business Wire
May-04-19 09:39PM  Heres What Hedge Funds Think About Deciphera Pharmaceuticals, Inc. (DCPH) Insider Monkey
Apr-10-19 12:20PM  Imagine Owning Deciphera Pharmaceuticals (NASDAQ:DCPH) And Wondering If The 16% Share Price Slide Is Justified Simply Wall St.
Mar-14-19 04:05PM  Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Year-end 2018 Financial Results Business Wire
Mar-06-19 07:20AM  Market Trends Toward New Normal in Exelon, AT&T, United States Cellular, Deciphera Pharmaceuticals, Boyd Gaming, and Argo Group International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire -5.40%
Mar-05-19 06:03AM  Deciphera CEO resigns, Ex-Agios exec to take over American City Business Journals
Mar-04-19 04:05PM  Deciphera Pharmaceuticals, Inc. Announces Retirement of Michael D. Taylor, Ph.D. Business Wire
Feb-07-19 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the 1st Annual Guggenheim Healthcare Talks Idea Forum Oncology Day Business Wire
Jan-17-19 03:50PM  Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table Investor's Business Daily
Jan-16-19 09:09AM  Deciphera Pharmaceuticals Shares March Higher, Can It Continue? Zacks
Jan-07-19 03:47PM  Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today Motley Fool +13.41%
Jan-03-19 07:30AM  Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Carboplatin in Patients with Advanced or Metastatic Solid Tumors Business Wire -8.14%
Jan-02-19 07:30AM  Deciphera Pharmaceuticals Announces Positive, Preliminary, Top-Line Clinical Data for the Ongoing Phase 1 Clinical Study with DCC-3014 and an Update on Future Development Plans Business Wire +7.10%
07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-27-18 07:20AM  Report: Developing Opportunities within AutoZone, Deciphera Pharmaceuticals, Clearwater Paper, Churchill Downs, Whitestone REIT, and ZTO Express (Cayman) Future Expectations, Projections Moving into 2019 GlobeNewswire
Dec-20-18 07:00AM  Deciphera Pharmaceuticals Initiates Pivotal Phase 3 Clinical Study of Ripretinib (DCC-2618) in Second-line Patients with Gastrointestinal Stromal Tumors (INTRIGUE Study) Business Wire
Dec-19-18 11:29PM  Is Deciphera Pharmaceuticals, Inc. (DCPH) A Good Stock To Buy? Insider Monkey -5.31%
Nov-20-18 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the 30th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-15-18 04:20PM  Deciphera Pharmaceuticals Completes Enrollment in the INVICTUS Pivotal Phase 3 Clinical Study of DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors Business Wire +10.45%
Nov-08-18 07:00AM  Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results Business Wire -7.79%
Oct-23-18 08:35AM  New Research Coverage Highlights Griffon, SEACOR, Deciphera Pharmaceuticals, Clearwater Paper, Comtech Telecommunications, and United Natural Foods Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
07:00AM  Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Paclitaxel to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced or Metastatic Solid Tumors Business Wire
Oct-19-18 08:00AM  Deciphera Pharmaceuticals Reports Updated Preliminary Phase 1 Clinical Study Results with DCC-2618 at the European Society of Medical Oncology (ESMO) 2018 Congress Business Wire -18.25%
Sep-25-18 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference Business Wire
Sep-18-18 07:30AM  Deciphera Pharmaceuticals Appoints Daniel C. Martin as Chief Commercial Officer GlobeNewswire
Aug-29-18 02:19PM  Why Raymond James Is Bullish On Deciphera, Dova Pharmaceuticals Benzinga
07:55AM  Report: Exploring Fundamental Drivers Behind CIRCOR International, Duluth, Griffon, Despegar, SEACOR, and Deciphera Pharmaceuticals New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
07:00AM  Deciphera Pharmaceuticals, Inc. to Participate in Citis 13th Annual Biotech Conference Business Wire
Aug-07-18 04:05PM  Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results Business Wire
Aug-01-18 07:00AM  Deciphera Pharmaceuticals, Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference Business Wire
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Allen Patricia LDirectorJan 24Sale66.1325,0001,653,3250Jan 28 04:13 PM
Martin Daniel C.Chief Commercial OfficerJan 22Option Exercise36.1026,999974,66443,999Jan 24 04:10 PM
Martin Daniel C.Chief Commercial OfficerJan 22Sale67.1826,9991,813,70917,000Jan 24 04:10 PM
Morl Christopher JohnChief Business OfficerJan 16Option Exercise3.953,01111,8933,011Jan 17 04:10 PM
Flynn Daniel LeeChief Scientific OfficerJan 16Option Exercise5.8066,906388,10391,406Jan 21 04:11 PM
Morl Christopher JohnChief Business OfficerJan 16Sale65.403,011196,9320Jan 17 04:10 PM
Morl Christopher JohnChief Business OfficerJan 15Option Exercise3.9512,02347,49112,023Jan 17 04:10 PM
Morl Christopher JohnChief Business OfficerJan 15Sale65.2312,023784,2740Jan 17 04:10 PM
Morl Christopher JohnChief Business OfficerJan 08Option Exercise3.9512,28148,51012,281Jan 09 04:10 PM
Morl Christopher JohnChief Business OfficerJan 08Sale60.1212,281738,2720Jan 09 04:10 PM
Morl Christopher JohnChief Business OfficerJan 07Option Exercise3.951,6506,5181,650Jan 09 04:10 PM
Morl Christopher JohnChief Business OfficerJan 07Sale60.021,65099,0350Jan 09 04:10 PM
Taylor Michael DouglasDirectorJan 03Option Exercise1.8931,42259,38831,422Jan 06 04:15 PM
Kelly Thomas PatrickChief Financial OfficerJan 03Option Exercise1.894,3598,2394,359Jan 06 04:15 PM
Bristol James ArthurDirectorJan 03Option Exercise1.897,98915,0997,989Jan 06 04:15 PM
Bristol James ArthurDirectorJan 03Sale57.357,989458,1950Jan 06 04:15 PM
Kelly Thomas PatrickChief Financial OfficerJan 03Sale57.354,359249,9930Jan 06 04:15 PM
Taylor Michael DouglasDirectorJan 03Sale57.3131,4221,800,9230Jan 06 04:15 PM
Morl Christopher JohnChief Business OfficerJan 02Option Exercise3.9516,13763,74116,137Jan 06 04:15 PM
Taylor Michael DouglasDirectorJan 02Option Exercise1.8993,578176,86293,578Jan 06 04:15 PM
Kelly Thomas PatrickChief Financial OfficerJan 02Option Exercise1.897,64114,4417,641Jan 06 04:15 PM
Bristol James ArthurDirectorJan 02Option Exercise1.8915,55329,39515,553Jan 06 04:15 PM
Bristol James ArthurDirectorJan 02Sale57.8315,553899,4680Jan 06 04:15 PM
Kelly Thomas PatrickChief Financial OfficerJan 02Sale57.817,641441,7480Jan 06 04:15 PM
Taylor Michael DouglasDirectorJan 02Sale57.8593,5785,413,1130Jan 06 04:15 PM
Morl Christopher JohnChief Business OfficerJan 02Sale58.5516,137944,8720Jan 06 04:15 PM
Kelly Thomas PatrickChief Financial OfficerDec 23Option Exercise1.8940,00075,60040,000Dec 26 04:05 PM
Kelly Thomas PatrickChief Financial OfficerDec 23Sale68.2140,0002,728,3680Dec 26 04:05 PM
Morl Christopher JohnChief Business OfficerDec 12Option Exercise3.9515,03459,38415,034Dec 13 05:00 PM
Morl Christopher JohnChief Business OfficerDec 12Sale60.0015,034902,0400Dec 13 05:00 PM
Flynn Daniel LeeChief Scientific OfficerDec 12Sale60.0031,0291,861,74035,750Dec 13 05:00 PM
Morl Christopher JohnChief Business OfficerDec 10Option Exercise3.9511,64746,00611,647Dec 11 04:30 PM
Flynn Daniel LeeChief Scientific OfficerDec 10Option Exercise1.89122,752232,001118,430Dec 11 04:10 PM
Flynn Daniel LeeChief Scientific OfficerDec 10Sale55.00122,7526,751,36024,500Dec 11 04:10 PM
Morl Christopher JohnChief Business OfficerDec 10Sale55.0011,647640,5850Dec 11 04:30 PM
Morl Christopher JohnChief Business OfficerDec 09Option Exercise3.953,38713,3793,387Dec 11 04:30 PM
Flynn Daniel LeeChief Scientific OfficerDec 09Option Exercise1.8930,17557,03154,675Dec 11 04:10 PM
Flynn Daniel LeeChief Scientific OfficerDec 09Sale55.0030,1751,659,62524,500Dec 11 04:10 PM
Morl Christopher JohnChief Business OfficerDec 09Sale55.003,387186,2850Dec 11 04:30 PM
Morl Christopher JohnChief Business OfficerDec 03Option Exercise0.0015,034015,034Dec 05 04:20 PM
Morl Christopher JohnChief Business OfficerDec 03Sale50.0015,034751,7630Dec 05 04:20 PM
Flynn Daniel LeeChief Scientific OfficerNov 11Option Exercise1.89143,185270,620167,685Nov 13 04:59 PM
Flynn Daniel LeeChief Scientific OfficerNov 11Sale48.01143,1856,874,87024,500Nov 13 04:59 PM
Flynn Daniel LeeChief Scientific OfficerNov 08Option Exercise1.899,74218,41234,242Nov 13 04:59 PM
Flynn Daniel LeeChief Scientific OfficerNov 08Sale48.009,742467,61624,500Nov 13 04:59 PM